vms

Minivelle® Available by Prescription Nationwide for Prevention of Postmenopausal Osteoporosis

Noven Pharmaceuticals, Inc. announced that the new 0.025 mg/day dosage strength for Minivelle® (estradiol transdermal system) is now available by prescription nationwide for only the prevention of postmenopausal osteoporosis. The FDA initially approved Minivelle in October 2012 to treat moderate to severe vasomotor symptoms (VMS) due to menopause, commonly known as hot flashes. In September 2014, …

Minivelle® Available by Prescription Nationwide for Prevention of Postmenopausal Osteoporosis Read More »

New Study on Duration of Menopausal Vasomotor Symptoms (Hot Flashes) Over the Menopause Transition

Hot flashes, night sweats and other symptoms of menopause typically affect women much longer than previously thought, a median of 7.4 years, according to a new study. The study, published in JAMA Internal Medicine, looked at a group of nearly 1,500 women with frequent symptoms of the onset of menopause and found significant variations in …

New Study on Duration of Menopausal Vasomotor Symptoms (Hot Flashes) Over the Menopause Transition Read More »

Scroll to Top